UROGEN PHARMA LTD (URGN) Stock Earnings & Estimates
USA - NASDAQ:URGN - IL0011407140 - Common Stock
23.13 USD
-0.11 (-0.47%)
23 USD
-0.13 (-0.56%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 64.36M 33.97% | 82.713M 28.52% | 90.398M 9.29% | 122.1M 35.07% | 265.97M 117.83% | 422.24M 58.75% | 539.87M 27.86% | 763.89M 41.50% | 996.18M 30.41% | 1.538B 54.39% | 1.674B 8.84% | |
| EBITDA YoY % growth | -78.12M 14.59% | -64.734M 17.14% | -96.453M -49.00% | -119.61M -24.01% | -56.518M 52.75% | 22.702M 140.17% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -79.04M 14.36% | -65.536M 17.09% | -96.782M -47.68% | -118.526M -22.47% | 6.044M 105.10% | 149.41M 2,372.04% | 271.49M 81.71% | 460.54M 69.63% | 665.07M 44.41% | 1.224B 84.04% | 1.334B 8.99% | |
| Operating Margin | -122.81% | -79.23% | -107.06% | -97.07% | 2.27% | 35.39% | 50.29% | 60.29% | 66.76% | 79.58% | 79.69% | |
| EPS YoY % growth | -4.78 3.57% | -3.73 22.02% | -3.23 13.40% | -3.24 -0.34% | -0.88 72.74% | 1.40 258.73% | 2.88 105.33% | 4.91 70.48% | 6.53 33.10% | 9.70 48.44% | 9.99 3.00% |
All data in USD
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.46 42.47% | -0.51 44.25% | -0.48 53.93% | -0.21 70.07% | -0.04 92.24% |
| Revenue Q2Q % growth | 43.823M 78.40% | 46.116M 127.69% | 56.545M 133.51% | 72.24M 162.86% | 83.091M 89.61% |
| EBITDA Q2Q % growth | -11.863M 56.59% | -19.064M 48.26% | N/A | N/A | N/A |
| EBIT Q2Q % growth | -15.195M 45.06% | -14.63M 60.37% | -11.25M 72.86% | -4.965M 80.34% | -3.371M 77.82% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2025 Q2Q % growth | -0.69 -25.45% | -0.71 | 0.02 | 2.31% |
| Q2 2025 Q2Q % growth | -1.05 -15.38% | -0.85 | -0.20 | -23.47% |
| Q1 2025 Q2Q % growth | -0.92 5.15% | -0.82 | -0.10 | -12.75% |
| Q4 2024 Q2Q % growth | -0.80 -11.11% | -0.73 | -0.07 | -8.93% |
| Q3 2024 Q2Q % growth | -0.55 19.12% | -0.83 | 0.28 | 34.01% |
| Q2 2024 Q2Q % growth | -0.91 11.65% | -0.85 | -0.06 | -7.23% |
| Q1 2024 Q2Q % growth | -0.97 25.38% | -0.88 | -0.09 | -9.81% |
| Q4 2023 Q2Q % growth | -0.72 40.98% | -0.69 | -0.03 | -3.81% |
| Q3 2023 Q2Q % growth | -0.68 39.98% | -0.86 | 0.18 | 21.20% |
| Q2 2023 Q2Q % growth | -1.03 12.71% | -1.16 | 0.13 | 11.11% |
| Q1 2023 Q2Q % growth | -1.30 -4.00% | -1.36 | 0.06 | 4.17% |
| Q4 2022 Q2Q % growth | -1.22 3.94% | -1.09 | -0.13 | -11.44% |
| Q3 2022 Q2Q % growth | -1.13 16.07% | -1.18 | 0.05 | 3.97% |
| Q2 2022 Q2Q % growth | -1.18 -0.85% | -1.30 | 0.12 | 9.27% |
| Q1 2022 Q2Q % growth | -1.25 -6.84% | -1.36 | 0.11 | 8.09% |
| Q4 2021 Q2Q % growth | -1.27 7.97% | -1.20 | -0.07 | -5.97% |
| Q3 2021 Q2Q % growth | -1.35 -3.05% | -1.32 | -0.03 | -2.47% |
| Q2 2021 Q2Q % growth | -1.17 18.75% | -1.15 | -0.02 | -1.87% |
| Q1 2021 Q2Q % growth | -1.17 34.64% | -1.32 | 0.15 | 11.42% |
| Q4 2020 Q2Q % growth | -1.38 25.81% | -1.40 | 0.02 | 1.34% |
| Q3 2020 Q2Q % growth | -1.31 -23.58% | -1.52 | 0.21 | 14.09% |
| Q2 2020 Q2Q % growth | -1.44 -33.33% | -1.61 | 0.17 | 10.77% |
| Q1 2020 Q2Q % growth | -1.79 -61.26% | -1.65 | -0.14 | -8.62% |
| Q4 2019 Q2Q % growth | -1.86 | -1.73 | -0.13 | -7.34% |
| Q3 2019 Q2Q % growth | -1.06 | -1.31 | 0.25 | 19.28% |
| Q2 2019 Q2Q % growth | -1.08 | -1.24 | 0.16 | 13.13% |
| Q1 2019 Q2Q % growth | -1.11 | -1.16 | 0.05 | 4.42% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2025 Q2Q % growth | 27.482M 9.04% | 33.755M | -6.273M | -18.58% |
| Q2 2025 Q2Q % growth | 24.215M 10.83% | 23.598M | 617K | 2.61% |
| Q1 2025 Q2Q % growth | 20.254M 7.84% | 23.26M | -3.006M | -12.92% |
| Q4 2024 Q2Q % growth | 24.565M 4.40% | 26.147M | -1.582M | -6.05% |
| Q3 2024 Q2Q % growth | 25.204M 20.87% | 24.688M | 516K | 2.09% |
| Q2 2024 Q2Q % growth | 21.848M 3.35% | 24.442M | -2.594M | -10.61% |
| Q1 2024 Q2Q % growth | 18.781M 9.24% | 21.809M | -3.028M | -13.88% |
| Q4 2023 Q2Q % growth | 23.53M 30.07% | 23.02M | 510K | 2.22% |
| Q3 2023 Q2Q % growth | 20.852M 29.52% | 20.43M | 422K | 2.07% |
| Q2 2023 Q2Q % growth | 21.139M 27.34% | 20.523M | 616K | 3.00% |
| Q1 2023 Q2Q % growth | 17.192M 26.78% | 17.525M | -333K | -1.90% |
| Q4 2022 Q2Q % growth | 18.09M 11.87% | 18.882M | -792K | -4.19% |
| Q3 2022 Q2Q % growth | 16.1M 41.85% | 20.549M | -4.449M | -21.65% |
| Q2 2022 Q2Q % growth | 16.6M 27.40% | 17.576M | -976K | -5.55% |
| Q1 2022 Q2Q % growth | 13.56M 81.04% | 15.482M | -1.922M | -12.41% |
| Q4 2021 Q2Q % growth | 16.17M 102.89% | 16.822M | -652K | -3.88% |
| Q3 2021 Q2Q % growth | 11.35M 228.03% | 15.728M | -4.378M | -27.84% |
| Q2 2021 Q2Q % growth | 13.03M 3,421.62% | 11.955M | 1.075M | 8.99% |
| Q1 2021 Q2Q % growth | 7.49M | 9.234M | -1.744M | -18.89% |
| Q4 2020 Q2Q % growth | 7.97M | 7.72M | 250K | 3.24% |
| Q3 2020 Q2Q % growth | 3.46M | 3.405M | 55K | 1.62% |
| Q2 2020 Q2Q % growth | 370K 1,750.00% | 264.517K | 105.483K | 39.88% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | -7.57% | -6.54% | -0.69% | -9.05% |
| Revenue | -4.67% | -1.78% | -3.26% | -3.39% |